590 related articles for article (PubMed ID: 11092994)
1. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
2. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
[TBL] [Abstract][Full Text] [Related]
3. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
4. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara I; Takahashi Y; Tanaka A; Koide H
Nephron; 2000 Oct; 86(2):247. PubMed ID: 11015024
[No Abstract] [Full Text] [Related]
5. Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.
Hemmelder MH; de Zeeuw D; de Jong PE
Nephrol Dial Transplant; 1999 Jan; 14(1):98-104. PubMed ID: 10052485
[TBL] [Abstract][Full Text] [Related]
6. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
Baumgart P; Reismann J; Pohlmeyer H; Düsing R
Dtsch Med Wochenschr; 2001 May; 126(19):547-50. PubMed ID: 11402910
[TBL] [Abstract][Full Text] [Related]
7. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
Homma K; Hayashi K; Kanda T; Yoshioka K; Takamatsu I; Tatematsu S; Kumagai H; Wakino S; Saruta T
J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
[TBL] [Abstract][Full Text] [Related]
8. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
[TBL] [Abstract][Full Text] [Related]
9. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
[TBL] [Abstract][Full Text] [Related]
10. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
[TBL] [Abstract][Full Text] [Related]
11. Verapamil versus amlodipine in proteinuric non-diabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial.
Boero R; Rollino C; Massara C; Vagelli G; Gonella M; Berto IM; Bajardi P; Perosa P; Malcangi U; Giorgi MP; Ghezzi PM; Borzumati M; Baroni AM; Cogno C; Triolo G; Angelini D; Antonelli A; Quarello F
J Nephrol; 2001; 14(1):15-8. PubMed ID: 11281338
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of trandolapril and candesartan cilexetil reduces microalbuminuria and urinary endothelin-1 excretion in patients with type 2 diabetes.
Nakamura T; Ushiyama C; Osada S; Takahashi Y; Shimada N; Ebihara I; Koide H
Clin Exp Nephrol; 2002 Sep; 6(3):135-9. PubMed ID: 24989952
[TBL] [Abstract][Full Text] [Related]
13. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Haneda M; Kikkawa R; Sakai H; Kawamori R;
Diabetes Res Clin Pract; 2004 Oct; 66(1):87-95. PubMed ID: 15364166
[TBL] [Abstract][Full Text] [Related]
14. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis.
Kurokawa K; Abe K; Saruta T; Arakawa M; Kikkawa R; Ueda N; Onoyama K; Tomita K; Ogawa N
J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):167-75. PubMed ID: 12563567
[TBL] [Abstract][Full Text] [Related]
15. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.
Rubio-Guerra AF; Arceo-Navarro A; Vargas-Ayala G; Rodriguez-Lopez L; Lozano-Nuevo JJ; Gomez-Harper CT
Diabetes Care; 2004 Jul; 27(7):1688-91. PubMed ID: 15220247
[TBL] [Abstract][Full Text] [Related]
16. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
Sugimoto K; Tsuruoka S; Matsushita K; Fujimura A
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923
[TBL] [Abstract][Full Text] [Related]
17. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H
Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
[TBL] [Abstract][Full Text] [Related]
19. Effect of strict blood pressure control on proteinuria in renal patients treated with different antihypertensive drugs.
García de Vinuesa S; Luño J; Gómez-Campderá F; Ridao N; Sánchez M; Dall'Anese C; Valderrábano F
Nephrol Dial Transplant; 2001; 16 Suppl 1():78-81. PubMed ID: 11369828
[TBL] [Abstract][Full Text] [Related]
20. Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats).
Noda M; Matsuo T; Nagano-Tsuge H; Ohta M; Sekiguchi M; Shibouta Y; Naka T; Imura Y
Jpn J Pharmacol; 2001 Apr; 85(4):416-22. PubMed ID: 11388646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
